Page 21 - Jon Burrows News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IN BRIEF: Oxford BioDynamics Annual Revenue Hurt By Covid-19 Pandemic Thu, 28th Jan 2021 20:25 Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Says 2020 was a year of transition and development with company readying for near-term commercialisation of its 3D genomics technology platform, EpiSwitch. Says R&D project revenues were affected by the Covid-19 pandemic. For year ended September 30, posts revenue of GBP456,000 down from GBP907,000 as pretax loss widens to GBP4.9 million from GBP3.4 million. Chief Executive Officer Jon Burrow...

About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch™, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. Oxford BioDynamics has participated in more than 40...

IN BRIEF: Oxford BioDynamics To Commercialise Laboratory Tests Tue, 15th Dec 2020 21:52 Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Expanding strategic focus beyond biomarker discovery to development and commercialisation of laboratory tests, via its EpiSwitch platform. Company intends to make its biomarker arrays and 3D genome bioinformatics tools available to the R&D market and to work closely with big pharma to leverage the insights of the 3D genome knowledgebase it has built. Intends to offer precision medicine testing via pa...